New Nomogram Predicts Significant Liver Fibrosis in Bile Duct Disease

Doctors managing primary biliary cholangitis (PBC), a chronic cholestatic liver disease, often need to know whether a patient has developed significant fibrosis, yet liver biopsy remains the definitive test. A new multicenter retrospective study, published in BMC Gastroenterology, reports the development and internal validation of a nomogram built entirely from routine blood tests that identifies significant fibrosis in PBC patients with notably better accuracy than established serum indices.

The research team enrolled 118 PBC patients who had undergone liver biopsy, dividing them into a significant fibrosis group, defined as Scheuer stage S2 or higher, with 69 patients, and a non-significant fibrosis group with 49 patients. Importantly, all enrolled patients were treatment-naive to ursodeoxycholic acid, the standard therapy for PBC, both before their liver biopsy and before baseline blood collection, which removes a potential confounder from the laboratory measurements used in the model.

Methodologically, the investigators used least absolute shrinkage and selection operator (LASSO) regression followed by multivariate logistic regression to identify independent predictors of significant fibrosis and to construct the nomogram. Four routine laboratory parameters made the final cut: platelet count, albumin, gamma-glutamyl transferase, and immunoglobulin G. The resulting tool assigns weighted points to each of these values, allowing clinicians to estimate an individual patient’s probability of significant fibrosis without an invasive procedure.

Performance testing showed an area under the receiver operating characteristic curve (AUROC) of 0.885, with a 95% confidence interval of 0.827 to 0.942. Calibration was good, with a Hosmer-Lemeshow test P value of 0.9485, indicating close agreement between predicted risks and observed outcomes. At the optimal cutoff, the nomogram achieved 73.9% sensitivity and 87.8% specificity. Internal validation, carried out through bootstrap resampling and 5-fold cross-validation, confirmed robustness, with a bootstrap AUROC of 0.869.

The model was also benchmarked against four conventional serum fibrosis indices: the aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 (FIB-4), the AST/ALT ratio (AAR), and the gamma-glutamyl transpeptidase-to-platelet ratio (GPR). Using DeLong’s test, the nomogram significantly outperformed all of these conventional indices, with all comparisons reaching P values below 0.05. The authors note that existing serum models often lack accuracy in cholestatic diseases such as PBC, which motivated the development of this disease-specific tool.

The study’s conclusion is that this nomogram, based on routine laboratory parameters, provides an accurate tool for the non-invasive risk stratification of significant fibrosis in PBC. Because the work is retrospective and internally validated only, with no external cohort, its findings represent model development and validation within the studied population rather than demonstrated performance in routine clinical practice. Even so, the combination of strong discrimination, good calibration, and superiority over APRI, FIB-4, AAR, and GPR marks a meaningful step toward reducing reliance on biopsy for staging fibrosis in this cholestatic liver disease.

Subject of Research: A nomogram using routine laboratory parameters to predict significant liver fibrosis in primary biliary cholangitis

Article Title: Development and internal validation of a nomogram for predicting significant liver fibrosis in primary biliary cholangitis: a multicenter retrospective study

Article References: Zhang, Y., Liu, Z., Bao, J., Zuo, Z., Pan, K., Xu, A., & Miao, T. (2026). Development and internal validation of a nomogram for predicting significant liver fibrosis in primary biliary cholangitis: a multicenter retrospective study. BMC Gastroenterology. https://doi.org/10.1186/s12876-026-05476-z

Image Credits: AI Generated

DOI: 10.1186/s12876-026-05476-z

Keywords: primary biliary cholangitis, liver fibrosis, nomogram, non-invasive diagnosis, LASSO regression, AUROC, serum biomarkers, hepatology, retrospective study, diagnostic model, Development, internal